CN115137740B - miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用 - Google Patents
miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用 Download PDFInfo
- Publication number
- CN115137740B CN115137740B CN202210319251.0A CN202210319251A CN115137740B CN 115137740 B CN115137740 B CN 115137740B CN 202210319251 A CN202210319251 A CN 202210319251A CN 115137740 B CN115137740 B CN 115137740B
- Authority
- CN
- China
- Prior art keywords
- mirna
- group
- treating
- ischemic
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000302 ischemic effect Effects 0.000 title claims abstract description 27
- 210000004165 myocardium Anatomy 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000013543 active substance Substances 0.000 claims abstract description 5
- 239000002773 nucleotide Substances 0.000 claims abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 4
- 238000011084 recovery Methods 0.000 claims abstract description 3
- 230000008685 targeting Effects 0.000 claims abstract 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 abstract description 11
- 239000002679 microRNA Substances 0.000 abstract description 9
- 208000029078 coronary artery disease Diseases 0.000 abstract description 5
- 230000014509 gene expression Effects 0.000 abstract description 4
- 208000010125 myocardial infarction Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 45
- 208000028867 ischemia Diseases 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 230000010410 reperfusion Effects 0.000 description 9
- 230000000747 cardiac effect Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 210000001808 exosome Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 239000006180 TBST buffer Substances 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 210000005240 left ventricle Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 5
- 210000003855 cell nucleus Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000002064 heart cell Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000005248 left atrial appendage Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 108010091987 aposome Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000035565 breathing frequency Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004704 glottis Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- XOSXWYQMOYSSKB-LDKJGXKFSA-L water blue Chemical compound CC1=CC(/C(\C(C=C2)=CC=C2NC(C=C2)=CC=C2S([O-])(=O)=O)=C(\C=C2)/C=C/C\2=N\C(C=C2)=CC=C2S([O-])(=O)=O)=CC(S(O)(=O)=O)=C1N.[Na+].[Na+] XOSXWYQMOYSSKB-LDKJGXKFSA-L 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及生物医学技术领域,尤其涉及了miRNA497b或miRNA5106在制备治疗缺血心肌的药物中的应用,包括miRNA‑497b与miRNA‑5106核苷酸序列,如SEQ ID NO:1、SEQ ID NO:2所示,miRNA‑497b或miRNA‑5106作为活性物质能够促进缺血心肌的恢复,miRNA‑497b或miRNA‑5106作为一种治疗缺血性心脏病的靶向药物。该miRNA497b或miRNA‑5106在制备治疗缺血心肌的药物中的应用,miRNA‑497b或miRNA‑5106可以直接作为活性物质治疗缺血心肌,使机体miRNA的表达量增多,广泛用于临床括冠心病以及心肌梗死的疾病治疗。
Description
技术领域
本发明涉及生物医学技术领域,具体为miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用。
背景技术
缺血性心脏病(IHD),也称为冠心病,包括由冠状动脉狭窄或阻塞引起的一种威胁人类健康的重大疾病。随着社会的不断发展,人民的生活节奏也在逐渐加快,抽烟、喝酒、熬夜以及高脂高热量的摄入这些不健康的生活方式正在威胁着人们的心血管健康。目前,冠心病较为有效的临床治疗方法有冠状动脉内溶栓法、冠脉内支架法、切割球囊技术以及心脏移植。虽然以上方法均可以对病情有所改善,但是大部分手术治疗都有一定程度的风险且并不适用于所有患者,比如,很大一部分的患者由于现有的并发症而不能进行心脏移植手术。因此,心脏再生疗法的最新进展已成为一种有吸引力的替代治疗方案。
微小RNA(microRNA,miRNA)是一类非编码的小分子单链RNA,长度大约为22个核苷酸。研究表明,miRNA可以对基因的表达进行调节,在细胞的生长发育、增殖、凋亡以及分化中起到了重要的作用。越来越多的证据表明miRNA可以通过不同的机制来对心脏起到保护作用,可以为心肌缺血的预防与治疗提供新的靶点与思路。
发明内容
本发明首次揭示了miRNA-497b或miRNA-5106与缺血心肌修复之间的关系,证明了miRNA-497b或miRNA-5106调节剂能够促进受损心肌细胞恢复。
为实现上述目的,本发明提供如下技术方案:miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用,所述miRNA-497b与miRNA-5106核苷酸序列为
5’-CACCACAGUGUGGUUUGGACGUGG-3’(SEQ ID NO:1)、
5’-AGGUCUGUAGCUCAGUUGGCAGA-3’(SEQ ID NO:2)。
优选的,所述miRNA-497b或miRNA-5106作为活性物质,或者作为药物活性靶点设计miRNA-497b或miRNA-5106增效剂,miRNA-497b或miRNA-5106或它们的增效剂能够修复缺血的心肌细胞。
优选的,所述增效剂是miRNA-497b或miRNA-5106模拟核酸。
优选的,所述miRNA的模拟物是通过化学合成的方法模拟生物体内源的miRNA,通过转染的方法转染进细胞内,可以达到增强内源性miRNA的功能的目的。
优选的,一种miRNA-497b或miRNA-5106增效剂,具体为miRNA-497b或miRNA-5106模拟核酸。
优选的,所述miRNA-497b或miRNA-5106或它们的增效剂治疗缺血心肌药物包括治疗冠心病以及心肌梗死的药物。
与现有技术相比,本发明的有益效果是:
1.该miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用,miRNA-497b或miRNA-5106可以直接作为活性物质治疗缺血心肌或者作为药物的靶点设计miRNA-497b或miRNA-5106的增效剂,来使机体miRNA的表达量增多,从而调控机体内其他因子的表达来治疗缺血心肌。
2.该miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用,miRNA-497b或miRNA-5106的模拟物能够调节心肌细胞的功能,达到治疗缺血心肌的目的,可以广泛用于临床括冠心病以及心肌梗死的疾病治疗。
附图说明
图1为miRNA-497b或miRNA-5106对缺血再灌注诱导H9C2损伤后细胞形态观察及其存活率情况图;
图2显示miRNA-497b或miRNA-5106对IR诱导H9C2损伤后LDH、SOD的影响图;
图3显示miRNA-497b或miRNA-5106对IR诱导H9C2损伤后ROS的影响图;
图4显示miRNA-497b或miRNA-5106对IR诱导H9C2损伤后PI3K/AKT蛋白水平的影响图;
图5显示miRNA-497b或miRNA-5106对缺血再灌注诱导小鼠心肌的影响图;
图6显示miRNA-497b或miRNA-5106对缺血再灌注诱导小鼠心肌纤维化的影响图;
图7显示miRNA-497b或miRNA-5106对缺血再灌注诱导后血清中BNP、CK-MB和hs-TnT含量的影响图。
图8显示miRNA-497b或miRNA-5106对缺血再灌注诱导后小鼠心功能的影响图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
请参阅图1-8,本发明提供一种技术方案:miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用,
实施例一:H9C2细胞的培养以及体外缺血模型的建立。
1)用含有10%FBS和2%青霉素-链霉素双抗溶液的DMEM培养基培养H9C2细胞,培养条件为5%CO2和37℃,每隔2-3天更换一次新鲜培养液,3-4天传代一次,取对数生长期的细胞用于实验。
2)将H9C2细胞以1×106个/孔接种至6孔板上,将其分为空白对照组(Con)、缺血组(MI)、和两组缺血后转染组(miRNA-497b与miRNA-5106),用培养基培养24小时后,去除旧培养基,将细胞用PBS清洗3遍。
3)缺血组与转染组用缺血液处理20min后,缺血组直接加入新培养基,转染组转染miRNA-497b与miRNA-5106于细胞中,空白对照组不做缺血处理。
4)加入后24h移出观察细胞形态。
实施例二:细胞存活率的检测
将H9C2细胞以1×105个/孔接种至96孔板上,每孔体积为200μL,用实施例二的方法制造体外缺血模型并分组,每组做6个平行组。根据试剂盒说明书要求在避光条件下向每孔加入20μLCCK-8溶液后,在培养箱孵中育2小时,用酶标仪测定450nm处的吸光值。
如图1所示,对比MI组(45.13±2.52)和Control组可以发现,MI组不仅细胞数量很少,且在缺血后细胞形态扭曲、部分细胞膜破碎,证明该缺血模型造模成功。转染组比MI组细胞存活率显著升高,但与Control组比较仍未恢复至正常水平。其中,空白对照组(Con):心脏细胞在无任何处理的对照培养24h;缺血组(MI):心脏细胞在缺血损伤后无任何后处理培养24h;实验组(miRNA-497b与miRNA-5106):心脏细胞在缺血损伤后转染miRNA-497b与miRNA-5106培养24h。
将miRNA模拟物转染到H9C2细胞后细胞形态以及细胞存活率并没有发生明显的改变,证明用PEI试剂转染6小时对细胞的影响并不大。对细胞缺血处理后,可以发现,转染miRNA的H9C2细胞的形态扭曲程度较弱、凋亡减少,且转染miRNA-5106后的细胞存活率要高于转染miRNA-497b。
注:图中星号表示与空白对照组存在显著性差异:p<0.05。
实施例三:Hoechst33258染色法观察细胞核型变化
用实施例一的方法制造体外缺血模型并分组,向6孔板中加入预冷的PBS对每孔细胞进行清洗,在室温的条件下用4%多聚甲醛固定液对细胞进行固定。固定20min后使用PBS进行清洗3次,每次3分钟。在避光条件下,加入Hoechst33258染色液,室温下孵育15min,最后再使用PBS进行清洗3次,每次3分钟,于超净台中避光风干,在荧光显微镜下用400×的放大倍数下观察细胞核的形态。
Control组的细胞核呈现出弥散均匀的淡蓝色荧光,色泽均一,形态规则且表面光滑。MI组与Control组相比,可见较强的蓝色荧光,这是程序性凋亡的细胞急剧增多,细胞出现细胞膜出泡、细胞核缩聚的现象,甚至可以观察到一些细胞的细胞核破裂染色质逸出并在核边聚集的现象。转染miRNA-497b后细胞核聚缩、破裂这些程序性细胞凋亡的特征愈逐渐减弱,呈现与Control组相似的弥散均匀的淡蓝色荧光。
实施例三:乳酸脱氢酶(LDH)细胞毒性试验与总SOD活性检测(WST-8法)
将H9C2细胞接种于96孔板上,并按实施例1的方法处理细胞并分组,加药孵育24小时后吸取120μL上清液至新的96孔板上,按照试剂盒说明书配制LDH检测工作液,分别向每孔加入60μLLDH检测工作液,混匀后在室温且避光的条件下水平摇床缓慢摇动30min,用酶标仪测定在490nm处的吸光值。
用实施例一的方法制造体外缺血模型并分组,用预冷的PBS洗涤细胞一次,再加入PBS用细胞刮刀将细胞刮下转移到离心管中,在4℃、1500rpm的条件下离心10分钟,去除上清液,每管加入70μL的裂解液(将RIPA裂解液与苯甲基硫酰氟按100:1的比例混匀,现配现用,置于冰上保存)并适当吹打以充***解细胞,在4℃的条件下水平摇床快速摇动30分钟。在4℃、13200rpm的条件下离心10分钟,将上清液转移至新的离心管,用BCA试剂盒测定蛋白浓度。依照说明书要求配制WST-8/酶工作液和反应启动液后,并按照说明书在低温条件下依次加入待测样品和其它工作液。
如图2所示,转染组的LDH释放量(112.17±6.59、119.00±5.17)明显低于MI组(157.17±4.54),且具有显著性差异。同时我们发现SOD的活性在缺血处理后相较于空白对照组明显降低(47.11±3.87),转染后SOD(84.70±5.22、81.94±3.48)活性增加,且具有显著性差异。以上结果表明转染miRNA-497b或miRNA-5106后可以增强H9C2细胞的抗氧化应激作用。
实施例四:活性氧(ROS)检测
用实施例一的方法制造体外缺血模型并分组,用预冷的PBS洗涤细胞一次。用培养液按照1000:1的比例稀释DCFH-DA,每孔加入1mL稀释后的DCFH-DA,然后在细胞培养箱中孵育20分钟,用无血清细胞培养液洗涤细胞三次后在激光共聚焦显微镜下观察并拍照。
如图4所示,MI组与Control组比较,MI组产的细胞数量急剧减少并产生大量的活性氧,表明该缺血再灌注模型可以导致氧化应激损伤从而致使细胞逐渐凋亡。转染组的细胞能够有效的阻止缺血再灌注所引起的活性氧含量的增加,并且对比MI组细胞的数量也明显的上升趋势。这些结果表明转染miRNA-497b或miRNA-5106能够减弱氧化应激所带来的损伤,从而来减少缺血心肌细胞的凋亡。
实施例五:蛋白印迹法检测
用实施例一的方法制造体外缺血模型并分组,用预冷的PBS洗涤细胞一次,再加入PBS用细胞刮刀将细胞刮下转移到离心管中,在4℃、1500rpm的条件下离心10分钟,去除上清液,每管加入70μL的裂解液(将RIPA裂解液与苯甲基硫酰氟按100:1的比例混匀,现配现用,置于冰上保存)并适当吹打以充***解细胞,在4℃的条件下水平摇床快速摇动30分钟。在4℃、13200rpm的条件下离心10分钟,将上清液转移至新的离心管,取5μL用BCA试剂盒定量。向剩余蛋白样品中加入3×的SDSloadingbuffer(使loadingbuffer的终浓度为1×),充分混匀后在100℃的沸水中煮5分钟,可存放于-80℃长期保存。
将上述蛋白样品解冻后按每孔10μg的蛋白量加入制作好的凝胶电泳槽中,进行聚丙烯酰胺凝胶电泳(SDS-PAGE)电泳。电泳结束后,将蛋白转移到硝酸纤维膜上,再用TBST清洗3次,每次5分钟。用5%脱脂牛奶在室温下封闭2小时后取出膜,继续用TBST清洗3次,每次5分钟。孵一抗(用含有5%BSA的TBST按照1000:1的比例稀释)过夜。第二天取出PVDF膜,用TBST清洗3次,每次10分钟。在室温下孵育相应的二抗(用含有5%BSA的TBST按照5000:1的比例稀释)1.5小时,取出PVDF膜,用TBST清洗3次,每次10分钟。加入ECL发光液并在分子成像***中显影、分析。
如图4所示,与Control组相比,MI组PI3K、p-AKT蛋白水平显著降低(P<0.01)转染组相应的蛋白水平得到增加,暗示转染miRNA-497b或miRNA-5106可以上调心肌细胞的PI3K/AKT通路发挥心肌缺血保护效应的作用。
实施例六:小鼠心肌缺血再灌注模型
用戊巴比妥钠80mg/kg腹腔注射麻醉,剃除小鼠胸部及腋下毛发以充分暴露手术区域,用碘伏和75%乙醇对手术区进行消毒。打开呼吸机,设置呼吸频率为110次/分,洗呼比为1:1.5,潮气量为1.5mL,将插管沿声门***小鼠气管,连接呼吸机,可观察到小鼠胸廓起伏与呼吸机频率保持一致。小鼠采用右侧卧位,用显微剪在左侧第3-4根肋骨之间剪开皮肤和肋间隙,用拉钩撑开肋骨充分暴露心脏。用显微直镊轻轻撕开左心耳处的心包膜,使左冠状动脉前降支(LAD)所在区域(左心耳中下1-2mm处)充分暴露。用7-0缝线垂直于LAD走向的方向打活结以结扎冠状动脉,假手术组以同样的手法暴露心脏但不结扎冠状动脉。缺血45分钟后,解开结扎线。转染组用微量进样器在梗死区域多点注射富含miRNA-497b的C-kit+心脏细胞外泌体25μg,缺血组用微量进样器在梗死区域多点注射等体积PBS。用4-0缝线由内向外逐层缝合各层肌肉和皮肤。术后每天关注小鼠状态,正常饲养。术后3天,取血后处死小鼠,用生理盐水对小鼠进行全身灌流后取出心脏,再用生理盐水冲洗掉表面血迹并用纱布擦干。用4%多聚甲醛进行固定。
实施例七:苏木素伊红(HE)染色
将实施例六的心脏,脱水包埋后切成厚度约为5μg的薄片。用二甲苯I、II、III、IV以及各个浓度的酒精对切片进行处理,再用流水冲洗。用苏木素染液将切片染色7分钟后用流水冲洗,再用盐酸酒精分化液分化,然后用稀氨水返蓝。用伊红染液将切片染色3分钟,再用流水冲洗。使用不同浓度的酒精和二甲苯I、III对切片进行脱水透明处理,待切片透明后封片。将染好的切片在显微镜下观察并进行分析。
结果如图5所示,取手术后3天的小鼠心脏进行HE染色,可以看出MI组与假手术组相比较比较,细胞周围间隙增宽且存在很多大小不等的空泡,细胞排列更为松散,细胞质染色程度不均匀,细胞核皱褶变形,具有明显的凋亡特征。外泌体组与MI组相比较,细胞周围间隙缩短、轮廓逐渐清晰、排列更为有序,细胞核恢复正常,心肌细胞数量增加,说明富含miRNA-497b或miRNA-5106的C-kit+心脏细胞外泌体对缺血心肌具有保护效应。
实施例八:Masson染色
用实施例六的方法对切片进行脱蜡水化,用Weigert铁苏木素染液将切片染色7分钟后用流水冲洗,再用盐酸酒精分化液分化,然后用稀氨水返蓝。用丽春红染液将切片染色5分钟,再用流水冲洗。用2%的冰醋酸水溶液清洗切片后,用1%磷钼酸水溶液处理切片并倾倒。苯胺蓝染液复染5分钟后将其倾去,2%的冰醋酸水溶液清洗切片至无蓝色脱出。使用不同浓度的酒精和二甲苯I、III对切片进行脱水透明处理,待切片透明后封片。将染好的切片在显微镜下观察并进行分析。
结果如图6所示,取手术后3天的小鼠心脏进行Masson染色,观察小鼠心肌纤维化情况,可以观察到MI组梗死区域周边发生大规模的纤维化,而外泌体给药组相较于MI组梗死区域周边纤维化明显减少,说明富含miRNA-497b或miRNA-5106的C-kit+心脏细胞外泌体可以通过减少缺血所导致的纤维化来达到保护缺血心肌的目的。
实施例九:酶联免疫吸附实验
用实施例6的方法制造小鼠心肌缺血再灌注模型,术后3天,用异氟烷麻醉小鼠,眼球取血,3000rpm的条件下离心5分钟,取上层血清于-80℃保存。使用ELISA试剂盒检测各组小鼠血清中BNP、CK-MB和hs-TnT的含量,并采用酶标仪进行定量分析,严格按照试剂盒说明书操作。
如图7所示,我们发现IR诱导后小鼠的血清中BNP、CK-MB和hs-TnT含量(分别为523.14±15.26pg/mL、83.11±2.66ng/mL、473.89±11.43ng/L)相较于空白对照组明显升高(分别为369.16±6.20pg/mL、50.37±1.40ng/mL、322.42±9.15ng/L),外泌体给药后小鼠的血清中BNP、CK-MB和hs-TnT含量(分别为448.87±13.58pg/mL、64.66±2.12ng/mL、382.02±10.01ng/L)显著降低,且具有显著性差异。以上结果表明富含miRNA-497b或miRNA-5106的C-kit+心脏细胞外泌体对缺血性心脏病具有一定的治疗作用。
实施例十:心脏超声检测心功能
分别将每组小鼠手术前以及手术后的第一天、第三天进行心超检测。用戊巴比妥钠麻醉小鼠后,在不扯开缝合处的情况下小心地剃除手术区域附近的毛发。将彩超仪的探头垂直于第3和第4根肋骨之间靠左放置,获取小鼠左心室(Leftventricle,LV)的胸骨旁长轴及短轴切面,得到M型超声心动图。分别测量左室收缩末期内径(Leftventricle end-systolic diameter,LVDs)、左室舒张末期内径(Leftventricle end-diastolicdiameter,LVDd)、左室收缩末期容积(Left ventricle end-systolic volume,LVVs)和左室舒张末期容积(Left ventricle end-diastolic volume,LVVd)。
如图8所示,在手术之前三组小鼠的心脏功能都保持在同一水平,但经过手术后,MI组和EXO组小鼠的左室短轴缩短率与左室射血分数均急剧降低,而sham组这两项指标无明显变化。EXO组小鼠的左室短轴缩短率与左室射血分数在手术后的第1天和第3天都要高于MI组,表明了向缺血心肌内注射C-kit+心脏细胞外泌体能够使心功能得到明显的恢复。手术后第三天,EXO组的左心室的舒张末期以及收缩末期内径要明显低于MI组,表明富含miRNA-497b或miRNA-5106C-kit+心脏细胞外泌体可以减轻缺血性心脏病所导致的心室形态的变化。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (3)
1.miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用,包括miRNA-497b或miRNA-5106核苷酸序列,其特征在于:所述miRNA-497b、miRNA-5106核苷酸序列分别如SEQID NO:1、SEQ ID NO:2所示。
2.根据权利要求1所述的miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用,其特征在于:所述miRNA-497b或miRNA-5106作为活性物质,miRNA-497b或miRNA-5106能够促进缺血心肌的恢复。
3.根据权利要求2所述的miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用,其特征在于:所述miRNA-497b或miRNA-5106作为一种用于治疗缺血性心脏病的靶向药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210319251.0A CN115137740B (zh) | 2022-03-29 | 2022-03-29 | miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210319251.0A CN115137740B (zh) | 2022-03-29 | 2022-03-29 | miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115137740A CN115137740A (zh) | 2022-10-04 |
CN115137740B true CN115137740B (zh) | 2023-12-12 |
Family
ID=83405743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210319251.0A Active CN115137740B (zh) | 2022-03-29 | 2022-03-29 | miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115137740B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104524599A (zh) * | 2014-12-19 | 2015-04-22 | 青岛大学 | 一种miRNA-532反义核苷酸药物组合物及其用途 |
WO2018031404A1 (en) * | 2016-08-10 | 2018-02-15 | Indiana University Research And Technology Corporation | Method for generating mesoderm and/or endothelial colony forming cell-like cells having in vivo blood vessel forming capacity |
CN110680828A (zh) * | 2019-10-11 | 2020-01-14 | 中国人民解放军第四军医大学 | miR-1192用于制备预防和治疗缺血性心脏病药物的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102921021B (zh) * | 2012-11-26 | 2014-05-21 | 中国科学院动物研究所 | miRNA-361及其反义核苷酸的用途 |
US9416369B2 (en) * | 2012-12-18 | 2016-08-16 | University Of Washington Through Its Center For Commercialization | Methods and compositions to modulate RNA processing |
ITUB20155765A1 (it) * | 2015-11-20 | 2017-05-20 | Braindtech S R L | Metodi per diagnosi, prognosi e monitoraggio terapeutico di patologie neurologiche, neurodegenerative e infiammatorie basati su microRNA contenuto in microvescicole microglia |
-
2022
- 2022-03-29 CN CN202210319251.0A patent/CN115137740B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104524599A (zh) * | 2014-12-19 | 2015-04-22 | 青岛大学 | 一种miRNA-532反义核苷酸药物组合物及其用途 |
WO2018031404A1 (en) * | 2016-08-10 | 2018-02-15 | Indiana University Research And Technology Corporation | Method for generating mesoderm and/or endothelial colony forming cell-like cells having in vivo blood vessel forming capacity |
CN110680828A (zh) * | 2019-10-11 | 2020-01-14 | 中国人民解放军第四军医大学 | miR-1192用于制备预防和治疗缺血性心脏病药物的应用 |
Non-Patent Citations (1)
Title |
---|
非编码RNA调节自噬参与缺血性心脏病的发生和发展;韩文静等;《青岛大学医学院学报》;第53卷(第5期);第628-630页前言、第2部分 * |
Also Published As
Publication number | Publication date |
---|---|
CN115137740A (zh) | 2022-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107224617A (zh) | 一种以脾脏细胞外基质为原料的水凝胶及其制备方法 | |
CN107385033B (zh) | piRNA-5938及其反义核酸在诊断、治疗缺血性心脏疾病中的应用 | |
Ren et al. | Physical properties of poly (N-isopropylacrylamide) hydrogel promote its effects on cardiac protection after myocardial infarction | |
CN115137740B (zh) | miRNA-497b或miRNA-5106在制备治疗缺血心肌的药物中的应用 | |
CN105194660B (zh) | 泛素特异蛋白酶18(usp18)在治疗心肌肥厚中的功能及应用 | |
CN105079785B (zh) | 三结构域蛋白32(trim32)在治疗心肌肥厚中的功能及应用 | |
CN113846098B (zh) | 一种小rna及其在心血管疾病治疗中的用途 | |
CN107625781B (zh) | miRNA抑制子在制备防治心肌梗死药物中的应用 | |
CN104141012B (zh) | Sh2b衔接蛋白1(sh2b1)在治疗心肌肥厚中的功能及应用 | |
CN114432332A (zh) | circUTRN在制备治疗心力衰竭药物中的应用、重组载体和治疗心力衰竭的药物 | |
CN105181976A (zh) | 三结构域蛋白8(trim8)抑制剂在抑制心肌肥厚中的功能及应用 | |
CN103893763B (zh) | Vinexin-β基因在心肌梗死中的应用 | |
CN106854660B (zh) | 携带人miR486基因的重组腺病毒、制备该病毒的载体及应用 | |
CN114588264B (zh) | 敲低或抑制egr3的试剂在制备心肌缺血再灌注损伤药物中的应用 | |
CN105194673A (zh) | 生长抑制特异性蛋白6(gas6)在治疗心肌肥厚中的功能及应用 | |
CN111568915A (zh) | miRNA-182、miRNA-188和miRNA-199a的抑制剂的应用 | |
CN113559266B (zh) | Ckip-1 3` UTR在预防和/或治疗心力衰竭疾病药物中的应用 | |
CN110714028B (zh) | 可控性上调Ang-(1-7)靶向性防治低氧性肺动脉高压的表达载体 | |
CN114517209B (zh) | 环状RNA circTTC3过表达腺相关病毒载体、腺相关病毒及其应用 | |
CN110433170B (zh) | 心脏抽吸液miR-28-5p在心脏疾病中的应用 | |
CN105194654B (zh) | 线粒体内膜转运蛋白50(tim50)在治疗心肌肥厚中的应用 | |
CN112587662A (zh) | 一种miR-155/PEA15信号通路抑制剂在病理性心脏重构药物中的应用 | |
CN106512009B (zh) | Ph同源域家族a成员3(phlda3)在治疗心肌肥厚中的应用 | |
CN116059366A (zh) | 一种搭载p16-siRNA的纳米药物的构建及其在治疗梗死后心室重塑中的应用 | |
CN111184736A (zh) | 抑制hmbox1基因表达的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |